Spots Global Cancer Trial Database for small cell lung cancer extensive stage
Every month we try and update this database with for small cell lung cancer extensive stage cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Small Doses of Etoposide as Maintenance Treatment in Small Cell Lung Cancer(SCLC) | NCT02179528 | Small Cell Lung... | Etoposide | 18 Years - | Peking University Cancer Hospital & Institute | |
| Molecular Analysis and Treatment Options of SCLC | NCT05945745 | Small-cell Lung... Small Cell Lung... Small Cell Lung... Small Cell Lung... Small Cell Lung... | Chemotherapy | 18 Years - | Shanghai Chest Hospital | |
| Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer | NCT04670445 | Stage IV Melano... Advanced Lung C... Stage IV Non-Sm... Unresectable No... Unresectable St... Small Cell Lung... Stage IV Merkel... Stage IV Cutane... Stage IV Basal ... Stage IV Breast... Stage IV Colore... Stage IV Gastri... Stage IV Esopha... Stage IV Hepato... Stage IV Renal ... Stage IV Bladde... Stage IV Head a... Stage IV Cervic... Stage IV Endome... Stage IV Mesoth... Immunotherapy Immune Checkpoi... | Educational Vid... Usual Care | 18 Years - | Massachusetts General Hospital | |
| Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer | NCT03325816 | Small Cell Lung... Small Cell Lung... | Nivolumab 177Lu-DOTA0-Tyr... | 18 Years - | Georgetown University | |
| SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer | NCT03755115 | Small Cell Lung... | Epirubicin plus... | 18 Years - 75 Years | Henan Cancer Hospital | |
| Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer | NCT05384015 | Small Cell Lung... | Lenvatinib Pembrolizumab Etoposide Carboplatin | 18 Years - | Fundación GECP | |
| KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer | NCT05027867 | Small-cell Lung... Small Cell Lung... Small Cell Lung... Small Cell Lung... | KRT-232 | 18 Years - | Kartos Therapeutics, Inc. | |
| Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC | NCT03994744 | Small-cell Lung... Small Cell Lung... Small Cell Lung... Small Cell Lung... | PD-1 inhibitor Metformin | 18 Years - 65 Years | Hunan Cancer Hospital | |
| IN10018 Combination Therapy in Treatment-naïve ES-SCLC | NCT06030258 | Small Cell Lung... | IN10018 Tislelizumab Carboplatin Etoposide | 18 Years - 75 Years | InxMed (Shanghai) Co., Ltd. | |
| Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer | NCT03923270 | Small Cell Lung... Small-cell Lung... | Durvalumab Tremelimumab Olaparib Pill Thoracic Radiot... Tremelimumab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer | NCT03755115 | Small Cell Lung... | Epirubicin plus... | 18 Years - 75 Years | Henan Cancer Hospital | |
| Thoracic Consolidation Radiotherapy for ES-SCLC Treated With Chemo-immunotherapy | NCT06187740 | Small Cell Lung... | thoracic radiot... | 18 Years - | Fudan University | |
| KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer | NCT05027867 | Small-cell Lung... Small Cell Lung... Small Cell Lung... Small Cell Lung... | KRT-232 | 18 Years - | Kartos Therapeutics, Inc. | |
| DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer | NCT05680922 | Small Cell Lung... Large Cell Neur... | LB2102 | 18 Years - | Legend Biotech USA Inc | |
| Immunotherapy as Second-line in Patient With Small Cell Lung Cancer | NCT03059667 | Small Cell Lung... Small Cell Lung... Small Cell Lung... | Atezolizumab Topotecan Carboplatin Etoposide | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease | NCT04462276 | Small Cell Lung... Thoracic Radiot... | Atezolizumab thoracic radiot... | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC | NCT04967625 | Small Cell Lung... | Sintilimab Anlotinib hydro... | 18 Years - | Zhejiang Cancer Hospital | |
| KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer | NCT05027867 | Small-cell Lung... Small Cell Lung... Small Cell Lung... Small Cell Lung... | KRT-232 | 18 Years - | Kartos Therapeutics, Inc. | |
| Immunotherapy as Second-line in Patient With Small Cell Lung Cancer | NCT03059667 | Small Cell Lung... Small Cell Lung... Small Cell Lung... | Atezolizumab Topotecan Carboplatin Etoposide | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer | NCT03325816 | Small Cell Lung... Small Cell Lung... | Nivolumab 177Lu-DOTA0-Tyr... | 18 Years - | Georgetown University | |
| DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer | NCT05680922 | Small Cell Lung... Large Cell Neur... | LB2102 | 18 Years - | Legend Biotech USA Inc | |
| Application of ctDNA in the Evaluation of Curative Effect and Prognosis of SCLC Patients | NCT05066945 | Small Cell Lung... | Observation | 18 Years - 80 Years | Xiangya Hospital of Central South University | |
| Antineoplaston Therapy in Treating Patients With Recurrent or Extensive-Stage Small Cell Lung Cancer | NCT00003496 | Small Cell Lung... | Antineoplaston ... | 18 Years - 99 Years | Burzynski Research Institute | |
| Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC | NCT03994744 | Small-cell Lung... Small Cell Lung... Small Cell Lung... Small Cell Lung... | PD-1 inhibitor Metformin | 18 Years - 65 Years | Hunan Cancer Hospital | |
| A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC） | NCT04659785 | Small Cell Lung... | Fluzoparib Apatinib | 18 Years - 70 Years | Tianjin Medical University Second Hospital | |
| Thoracic Consolidation Radiotherapy for ES-SCLC Treated With Chemo-immunotherapy | NCT06187740 | Small Cell Lung... | thoracic radiot... | 18 Years - | Fudan University | |
| DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer | NCT05680922 | Small Cell Lung... Large Cell Neur... | LB2102 | 18 Years - | Legend Biotech USA Inc | |
| Study of Small Doses of Etoposide as Maintenance Treatment in Small Cell Lung Cancer(SCLC) | NCT02179528 | Small Cell Lung... | Etoposide | 18 Years - | Peking University Cancer Hospital & Institute | |
| Thoracic Consolidation Radiotherapy for ES-SCLC Treated With Chemo-immunotherapy | NCT06187740 | Small Cell Lung... | thoracic radiot... | 18 Years - | Fudan University | |
| Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer | NCT03923270 | Small Cell Lung... Small-cell Lung... | Durvalumab Tremelimumab Olaparib Pill Thoracic Radiot... Tremelimumab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients | NCT05703971 | Small Cell Lung... | quaratusugene o... atezolizumab | 18 Years - | Genprex, Inc. | |
| Antineoplaston Therapy in Treating Patients With Recurrent or Extensive-Stage Small Cell Lung Cancer | NCT00003496 | Small Cell Lung... | Antineoplaston ... | 18 Years - 99 Years | Burzynski Research Institute | |
| Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer | NCT03253068 | Small Cell Lung... | Pembrolizumab p... | 20 Years - | Wakayama Medical University | |
| IN10018 Combination Therapy in Treatment-naïve ES-SCLC | NCT06030258 | Small Cell Lung... | IN10018 Tislelizumab Carboplatin Etoposide | 18 Years - 75 Years | InxMed (Shanghai) Co., Ltd. | |
| Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer | NCT05384015 | Small Cell Lung... | Lenvatinib Pembrolizumab Etoposide Carboplatin | 18 Years - | Fundación GECP |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
